Trevi Therapeutics
Latest round
- Series C
Last raised
- Jul 2017
Total raised
- $93M
Investors
- 6
About Trevi Therapeutics
Trevi Therapeutics, Inc.Founded in 2011, Trevi Therapeutics, Inc. is based in New Haven, US. The company is dedicated to developing its investigational product, Haduvio, for chronic cough caused by idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Jennifer Good serves as the CEO and founder and has a history of founding other companies.Trevi Therapeutics is focused on the development of its investigational product, Haduvio (oral nalbuphine ER), which targets chronic cough conditions, particularly in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio operates through a unique mechanism by acting as a kappa agonist and mu antagonist (KAMA), aiming to alleviate the hypersensitivity disorder contributing to chronic cough. Haduvio addresses the physical, psychological, and social challenges faced by patients, which affect up to 10% of adults.S. for these conditions, emphasizing the medical need Trevi aims to fulfill.S.Trevi Therapeutics is engaged in clinical trials to advance Haduvio's development, focusing on potential revenue generation following market approval and commercialization of the product. The business model emphasizes direct-to-consumer strategies, especially targeting healthcare providers to prescribe Haduvio. Revenue generation is expected upon product market entry, with healthcare professionals likely to recommend Haduvio for chronic cough treatment. Pricing strategies will reflect the unique value proposition of Haduvio, aligning with industry standards for similar therapies.00 mn to advance the clinical development of Haduvio and explore potential new products aimed at chronic cough conditions.S. market, targeting specific patient populations suffering from chronic cough resulting from IPF and RCC.
Who invested in Trevi Therapeutics
6 investors across 4 rounds
See all investors in Trevi Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Trevi Therapeutics
Who invested in Trevi Therapeutics?
Trevi Therapeutics has 6 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Trevi Therapeutics raised?
Trevi Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Trevi Therapeutics last raise money?
Trevi Therapeutics's most recent round on record is a Series C, in Jul 2017.
What does Trevi Therapeutics do?
Trevi Therapeutics is a pharmaceuticals company.
Where is Trevi Therapeutics headquartered?
Trevi Therapeutics is headquartered in New Haven, US.
Which VCs invest in companies like Trevi Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Trevi Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Trevi Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.